EyePoint Pharmaceuticals (EYPT) stock fell more than 71% on August 17, 2026, hitting a 52-week low of $4.06, after the company reported topline results from its pivotal Phase 3 LUGANO trial. The trial tested DURAVYU 2.7 mg in patients with wet age-related macular degeneration, and the drug failed to meet its primary visual acuity endpoint when measured across the full patient dataset.

That full-dataset endpoint is the key regulatory bar, and it is the headline investors reacted to. The sell-off was swift, reflecting how much of EyePoint’s near-term story has been tied to this one readout.

Ad hoc analysis shows non-inferiority

EyePoint did offer some context around the miss. In an ad hoc analysis that excluded a small, asymmetric cohort of patients whose vision loss was unrelated to wet AMD, DURAVYU showed non-inferiority to on-label aflibercept. Ad hoc analyses, however, carry less regulatory weight than the pre-specified primary endpoint, and the market priced that distinction in quickly.

The secondary results were genuinely strong. DURAVYU reduced treatment burden by 42% compared with aflibercept. Patients also showed high supplement-free rates through Week 56, solid anatomic control, and a clean safety profile with repeat dosing.

For a wet AMD treatment, that mix matters because the commercial case in retinal disease often depends not just on visual outcomes, but also on whether a therapy can reduce the frequency of injections and still preserve control of the disease.

What the data actually shows

The drug did not fail outright. It missed on the full-dataset primary endpoint, which is the key regulatory measure, but the overall picture is more mixed than the stock price drop suggests.

EyePoint is now pointing to its second pivotal Phase 3 trial, LUCIA, with data expected in late 2026. A U.S. regulatory filing remains on the table for the first half of 2027, pending the LUCIA results, though that path now depends heavily on what the second trial delivers.

The company also has parallel Phase 3 programs running in diabetic macular edema, keeping the pipeline active beyond the wet AMD indication and giving investors another clinical catalyst to watch after the LUGANO setback.

Analyst targets still far above current price

Before the trial results, Mizuho had raised its price target on EYPT to $39, maintaining an Outperform rating. Stifel had initiated coverage with a Buy rating and a $40 price target.

The most recent analyst rating on record is a Buy with a $39 price target. That implies enormous upside from current levels, though those targets pre-date the new data and may be revised.

EYPT carries a beta of 1.74, reflecting how volatile the stock has been. Even before the drop, shares were up 33% over the prior 12 months, showing how sharply binary clinical readouts can swing a biotech.

Governance and financial position

Stockholders recently approved an amendment to EyePoint's 2023 Long-Term Incentive Plan, adding 4.9 million authorized shares. Directors including Göran Ando, M.D., and Jay S. Duker, M.D., were elected at the 2026 Annual Meeting to serve through 2027.

EyePoint's current market cap sits at approximately $1.27 billion. The company has stated it has cash runway into Q4 2027, which gives it time to advance the next data readout and its other late-stage programs. LUCIA Phase 3 data is expected in late 2026.